Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Hiscox CEO invests; Coca-Cola HBC counsel exercises, sells options

(Sharecast News) - Hiscox was among those on the list of director buys on Friday, after its chief executive officer added to his holding. The FTSE 100 company said Aki Hussain picked up 15,000 shares on 29 August, in a single transaction on the London Stock Exchange.

Hussain paid 1,004p for each share, valuing the transaction at a total of £150,600.

On the selling side of the ledger was Coca-Cola HBC, after its general counsel and company secretary exercised a tranche of share options before selling the shares.

The FTSE 100 drinks bottling giant said Jan Gustavsson exercised 30,000 share options at a strike price of 1,256p apiece, giving that side of the transaction a value of £376,800.

Gustavsson then sold the 30,000 shares on London's market, at a price of 2,310p apiece, giving the sale on 31 August a value of £693,000.

At 1317 BST, shares in Hiscox were up 0.75% at 1,005p, while those in Coca-Cola HBC were 0.66% weaker at 2,263p.

Reporting by Josh White for Sharecast.com.

Top Director Buys

Hiscox Limited (di) (HSX) Director name: Hussain,Hamayou Akbar Amount purchased: 15,000 @ 1,004.00p Value: �150,600.00

Vaalco Energy, Inc (di) (EGY) Director name: Maxwell,George Walter Mitchell Amount purchased: 5,000 @ $4.11 Value: $16,945.25

Vaalco Energy, Inc (di) (EGY) Director name: Fawthrop,Andrew L Amount purchased: 4,000 @ $4.11 Value: $13,549.93

Top Director Sells

Coca-cola Hbc Ag (cdi) (CCH) Director name: Bogdanovic,Zoran Amount sold: 5,528 @ 2,315.00p Value: �127,973.20

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 2,425 @ $3.70 Value: $7,398.78

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 1,501 @ $3.70 Value: $4,579.62

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 393 @ $3.70 Value: $1,200.68

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 393 @ $3.70 Value: $1,200.68

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 309 @ $3.73 Value: $950.42

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 165 @ $3.72 Value: $506.14

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 107 @ $3.71 Value: $327.34

Maxcyte (di) (MXCT) Director name: Johnston ,John Amount sold: 100 @ $3.70 Value: $305.10

Share this article

Related Sharecast Articles

Director dealings: Jadestone CEO snaps up shares
(Sharecast News) - Jadestone Energy revealed on Wednesday that chief executive Alexander Blakeley had acquired 443,100 ordinary shares in the AIM-listed upstream production company.
Director dealings: Travis Perkins CEO snaps up shares
(Sharecast News) - Travis Perkins revealed on Tuesday that chief executive Pete Redfern had acquired 249,218 ordinary shares in the FTSE 250-listed builders' merchant.
Director dealings: Arcontech CEO invests, Hargreaves Services director conducts sale-and-repurchase
(Sharecast News) - Matthew Jeffs, chief executive officer of Arcontech Group, disclosed a series of personal share purchases in the company on Monday, amounting to a total of 60,000 ordinary shares.
Director dealings: Haleon's Alan Stewart snaps up shares
(Sharecast News) - Haleon revealed on Friday that non-executive director Alan Stewart had acquired 33,923 ordinary shares in the London-listed consumer healthcare business.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.